Clinical Trials Logo
  1. Home
  2. Conjunctivitis, Allergic
  3. NCT00311844

A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)

Conjunctivitis, Allergic Clinical Trial

Official title:
A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms

Clinical Trial Summary

This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00311844
Study type Interventional
Source Organon and Co
Contact
Status Completed
Phase Phase 4
Start date March 1, 2005
Completion date May 28, 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT01470118 - A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase 4
Completed NCT03709121 - A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Phase 1/Phase 2
Completed NCT02555761 - Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Completed NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Phase 4
Recruiting NCT04299399 - Corneal Biomechanical Changes of Allergic Conjunctivitis
Completed NCT00917488 - Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP). Phase 2
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A
Completed NCT02082262 - AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Phase 3
Withdrawn NCT01541904 - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Phase 2
Completed NCT02161146 - AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase 3
Completed NCT00718744 - Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units Phase 2
Recruiting NCT03186755 - Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Phase 4
Completed NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea N/A
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT01289431 - Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis Phase 2
Completed NCT00655109 - A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Phase 4
Completed NCT00424398 - Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Phase 2/Phase 3
Completed NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis Phase 2